Search Results

issues Another Wild Ride? BY LEAH RALPH Congress rang in the New Year with a massive tax overhaul and a government shutdown over immigration—another unpredictable year in Washington, D.C., seems like a foregone conclusion. Now several months into 2018, is the turbulence slowing down or ratcheting up? Although MedPAC’s January vote recom- mended that Congress eliminate the Merit-Based Incentive …

In August 2015 the Health Resources and Services Administration (HRSA) released its much-anticipated “mega-guidance” on the 340B Drug Pricing Program, proposing new limits on the program but stopping short of a complete overhaul, prompting mixed reviews from stakeholders.

Summer headlines have been dominated by congressional efforts to repeal and replace portions of the Affordable Care Act (ACA) and find a politically palatable path forward to shoring up the nongroup insurance market.

In early March, the Centers for Medicare and Medicaid Services (CMS) issued a proposal to implement a national demonstration program that would fundamentally change the way Medicare pays physicians and hospitals for Part B drugs.